| Knockdown of ACAT-1 reduces amyloidogenic processing of APP. | |
| | |
MedLine Citation:
|
PMID: 17412327 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Previous studies have shown that acyl-coenzyme A:cholesterol acyl transferase (ACAT), an enzyme that controls cellular equilibrium between free cholesterol and cholesteryl esters, modulates proteolytic processing of APP in cell-based and animal models of Alzheimer's disease. Here we report that ACAT-1 RNAi reduced cellular ACAT-1 protein by approximately 50% and cholesteryl ester levels by 22% while causing a slight increase in the free cholesterol content of ER membranes. This correlated with reduced proteolytic processing of APP and 40% decrease in Abeta secretion. These data show that even a modest decrease in ACAT activity can have robust suppressive effects on Abeta generation. |
| | |
Authors:
|
Henri J Huttunen; Christopher Greco; Dora M Kovacs |
Related Documents
:
|
6830837 - Influence of diets on acyl-coa:cholesterol acyltransferase and on acyl-coa:retinol acyl... 3241127 - Effects of dietary retinoid and triglyceride on the lipid composition of rat liver stel... 10511297 - Advances in understanding of the role of lecithin cholesterol acyltransferase (lcat) in... 8068007 - Application of simultaneous spleen and liver perfusion to the study of reverse choleste... 8432427 - Persistent dysregulation of iga production and iga nephropathy in the b6c3f1 mouse foll... 2514227 - Dissolution of human brown pigment biliary stones. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2007-03-30 |
Journal Detail:
|
Title: FEBS letters Volume: 581 ISSN: 0014-5793 ISO Abbreviation: FEBS Lett. Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-04-10 Completed Date: 2007-06-13 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 0155157 Medline TA: FEBS Lett Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1688-92 Citation Subset: IM |
Affiliation:
|
Neurobiology of Disease Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, United States. Henri_Huttunen@hms.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amyloid beta-Peptides
/
metabolism* Cholesterol Esters / analysis, metabolism Endoplasmic Reticulum / enzymology Humans RNA Interference RNA, Small Interfering / pharmacology Sterol O-Acyltransferase / antagonists & inhibitors, genetics, metabolism* |
| Grant Support | |
ID/Acronym/Agency:
|
R01 NS045860-05/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid beta-Peptides; 0/Cholesterol Esters; 0/RNA, Small Interfering; EC 2.3.1.26/Sterol O-Acyltransferase; EC 2.3.1.26/sterol O-acyltransferase 1 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibition of hepatic glucose 6-phosphatase system by the green tea flavanol epigallocatechin gallat...
Next Document: Growth-associated protein 43-positive sensory nerve fibers accompanied by immature vessels are locat...